ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2017
Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR) for Patients with Lung Tumors and Severe Pulmonary Disease.Journal of clinical medicine · 2026Article
- Stereotactic ablative body radiation therapy for treatment of ultra-central lung tumors: a narrative review.Journal of thoracic disease · 2025Review
- Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial.International journal of radiation oncology, biology, physics · 2024Article
- Evaluation of tumour motion and internal/external correlation in lung SABR.The British journal of radiology · 2023Article
- Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy.Journal of translational medicine · 2023Review
- New Frontiers in Colorectal Cancer Treatment Combining Nanotechnology with Photo- and Radiotherapy.Cancers · 2023Review
- Outcomes Following SBRT vs. IMRT and 3DCRT for Older Patients with Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm.Clinical lung cancer · 2023Article
- Developments in radiation techniques for thoracic malignancies.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Late Central Airway Toxicity after High-Dose Radiotherapy: Clinical Outcomes and a Proposed Bronchoscopic Classification.Cancers · 2021Article
- Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns.Journal of radiosurgery and SBRT · 2021Article
- Immunomodulatory Effects of Radiotherapy.International journal of molecular sciences · 2020Review
- Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2020Article
- Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges.Journal of nanobiotechnology · 2020Review
- Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer.Cureus · 2019Article
- Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer.Translational lung cancer research · 2019Review
- Combining radiation plus immunotherapy to improve systemic immune response.Journal of thoracic disease · 2018Review
- Fatal Radiation Pneumonitis: Literature Review and Case Series.Advances in radiation oncologyArticle
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStereotactic ablative radiotherapy (SABR) is currently not the guideline-recommended treatment for lung tumors measuring more than 5 cm. However, improvements in radiotherapy techniques have led to increasing use of SABR for larger tumors.
methodsWe analyzed the clinical outcomes in patients with a primary or recurrent NSCLC measuring more than 5 cm and treated with five or eight fractions of SABR at our center. Patients who had prior thoracic radiotherapy were excluded.
resultsA total of 63 consecutive patients with a median tumor diameter of 5.8 cm (range 5.1-10.4) were identified; 81% had T2N0 disease and 18% had T3N0 disease. The median Charlson comorbidity index was 2 (range 0-6). After a median follow-up of 54.7 months, median survival was 28.3 months. Disease-free survival at 2 years was 82.1%, and the local, regional, and distant control rates at 2 years were 95.8%, 93.7%, and 83.6%, respectively. An out-of-field distant recurrence at one or more sites was the most common pattern of failure (10%). Grade 3 or higher toxicity was recorded in 30% of patients, with radiation pneumonitis being the most common toxicity (19%). A likely (n = 4) or possible (n = 8) treatment-related death was scored in 19% of patients. There was preexisting interstitial lung disease in eight patients (13%), with fatal toxicity developing in five of them (63%).
conclusionsLung SABR in tumors larger than 5 cm resulted in high local control rates and acceptable survival outcomes in a patient population with appreciable comorbidity. Patients with interstitial lung disease should be considered a very high-risk population for SABR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.